Opinion|Videos|May 22, 2026
Frontline Zanubrutinib Efficacy in High-Risk Del(17p) CLL
Author(s)Andrew H. Lipsky, MD
Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next treatment.
Advertisement
Episodes in this series
Andrew H. Lipsky,MD, discusses the strong long-term efficacy outcomes with frontline zanubrutinib (Brukinsa) monotherapy in patients with high-risk chronic lymphocytic leukemia and del(17p) alterations, as demonstrated in the 6-year update of the SEQUOIA trial. He emphasizes how these extensive 6-year follow-up data fully elucidate the progression-free survival benefit of zanubrutinib in this high-risk population.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
3
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
4
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
5